Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

I. Scher, Howard; Fizazi, Karim; Saad, Fred; Taplin, Mary‐Ellen; N. Sternberg, Cora; Miller, Kurt; de Wit, Ronald; F.A. Mulders, Peter; N., Kim; D. Shore, Neal; J. Armstrong, Andrew; W. Flaig, Thomas; Fléchon, Aude; N. Mainwaring, Paul; T. Fleming, Mark; D. Hainsworth, John; Hirmand, Mohammad; Selby, Bryan; Seely, Lynn; S. de Bono, Johann

doi:10.1056/nejmoa1207506

Public

Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

Published in New England Journal of Medicine • Aug 15, 2012

Authors:

Howard I. Scher

Karim Fizazi

Fred Saad

Abstract

BACKGROUND: Enzalutamide (formerly called MDV3100) targets multiple steps in the androgen-receptor-signaling pathway, the major driver of prostate-cancer growth. We aimed to evaluate whether enzalutamide prolongs survival in men with castration-resistant prostate cancer after chemotherapy. METHODS: ...

Subject

Enzalutamide

Prostate cancer

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!